Exclusive Commercialization Partnership With Clinigen for Xervyteg® in aGvHD

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

February 3, 2026

February 3, 2026: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

January 20, 2026

January 20, 2026: MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

December 8, 2025

December 8, 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

Like what you see? See more posts

Our upcoming events

Event
January 6, 2026

Microbiome Movement Summit 2026

Microbiome Movement Summit EU 2026 - January 27-29, 2026
MaaT Pharma
Event
January 6, 2026

Microbiome Times Forum 2026

Microbiome Times Forum 2026 - March 18-19, 2026
MaaT Pharma
Event
January 6, 2026

EBMT Annual Meeting 2026

EBMT 2026 - March 22-25, 2026
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers